| Acute and Chronic Complications
Acute and Chronic Complications

Effects of Empagliflozin on Glucose Metabolism and Body Fat Composition in Patients with Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

book_2 Source: ADA 2020 - Poster session
calendar_today Published on Medfyle: July 2020
headphones 3 min

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • Beneficial effects of SGLT2 inhibitors on glucose metabolism, body adiposity, and liver fat content are well established in diabetes.
  • As the mode of action of SGLT2 inhibitors partly depends on elevated blood glucose, we now investigate if these effects also occur in prediabetes.
  • Treatment with empagliflozin for 8 weeks had no major effects on glucose metabolism.
  • Though, SGLT2 inhibition reduced body adiposity and liver fat content, presumably by shifting energy metabolism towards lipid oxidation.
  • Empagliflozin might represent a treatment option for obesity and hepatic steatosis in prediabetes, independent of drug effects on blood glucose.
Presenting Author
Read more arrow_downward Hide arrow_upward

Julia Hummel MSc, PhD

Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich, University of Tübingen
German Center for Diabetes Research, Neuherberg, Germany